Follow the Money: Inside the Lydac Neuroscience Insolvency
The Men Behind Wellbeing — Chapter Eight
Lydac Neuroscience held intellectual property associated with Stephen Ray's microvesicle research. Andrew Chancellor later became a director. Then, in December 2018, the biotechnology company entered administration. This time, we move beyond the patent records and into the insolvency file itself.
At the end of Chapter Seven, I said there was one set of documents I wanted to see next.
The insolvency records.
Not another interview.
Not another corporate biography.
Not another explanation of Cell-Free Therapy.
The documents produced when Lydac Neuroscience Limited could no longer continue normally as a company.
That distinction matters.
When a company enters formal insolvency, the language changes.
Administrators have responsibilities to creditors.
Assets have to be identified.
Financial positions have to be documented.
Reports have to be filed.
And decisions taken during the insolvency process can leave a documentary trail.
That makes Lydac's insolvency particularly important to this investigation.
Because Lydac was not simply an ordinary company.
As established in the previous chapters, it was associated with intellectual property concerning Stephen Ray's microvesicle research.
And by the time Lydac entered administration, Andrew Chancellor was its director. Companies House records his appointment on 26 November 2014. (Companies House)
So the question now becomes:
What happened when the company ran into financial trouble—and what happened to the science?
The Insolvency File Is Much Larger Than a Single Notice
The Companies House filing history reveals something that is easy to miss if we simply look at Lydac's current status.
There is an extensive insolvency paper trail.
The public record includes:
a statement of affairs;
an administrator's proposal;
the result of a creditors' meeting;
an administrator's progress report;
the move from administration into creditors' voluntary liquidation;
multiple subsequent liquidators' statements of receipts and payments;
and finally the closing documents preceding dissolution.
Companies House records a nine-page statement of affairs filed on 28 January 2019 and a 31-page administrator's proposal filed on 9 April 2019. (Companies House)
This is important.
Lydac did not simply vanish.
There was a formal insolvency process lasting years.
And somewhere inside that process lies the financial history of the company's collapse.
Lydac Entered Administration in December 2018
The formal appointment took place on:
17 December 2018.
The administrators were:
Ian Robert
and
Christopher Purkiss
of Kingston Smith & Partners LLP.
The official Gazette notice described Lydac's business as:
Research and experimental development on biotechnology.
Its principal trading address was:
10 Harley Street, London W1G 9PF. (The Gazette)
This wasn't a company that had merely been struck from the register for failing to submit paperwork.
Administrators were formally appointed.
That means we need to understand what financial circumstances brought the company to that point.
Something Strange Appears in the Accounts
Before examining the insolvency itself, another part of the Companies House record deserves attention.
Lydac was registered as a biotechnology research company.
It was associated with patents.
It maintained a Harley Street address.
Andrew Chancellor was its director.
And yet its Companies House filing history shows dormant accounts for several years immediately preceding administration.
Companies House records dormant accounts for the years ending:
30 September 2015
30 September 2016
and:
30 September 2017. (Companies House)
The last accounts filed before administration were for the year ending 30 September 2017.
Those accounts were again classified as dormant.
That creates an obvious question.
How Does a Dormant Biotechnology Company Reach Administration?
A dormant company is not necessarily meaningless.
A company may hold intellectual property while conducting little or no accounting activity.
Commercial operations may occur elsewhere.
Assets may be licensed.
Corporate structures can separate intellectual-property ownership from trading operations.
So dormant accounts are not evidence of wrongdoing.
But they do make the insolvency considerably more interesting.
If Lydac was dormant, what liabilities subsequently resulted in administration?
Was the company carrying historic debt?
Was money owed to investors?
Were there loans?
Were there patent costs?
Professional fees?
Legal costs?
Connected-company balances?
Or liabilities that did not appear in the simplified dormant accounts?
These are exactly the questions the statement of affairs and administrator's proposal should help answer.
There Had Already Been a Strike-Off Warning
The filing history reveals another event before the insolvency.
On 30 August 2016, a First Gazette notice for compulsory strike-off was issued against Lydac.
That strike-off action was discontinued on 1 October 2016. (Companies House)
Again, this does not demonstrate financial misconduct.
Compulsory strike-off proceedings can arise from administrative failures such as overdue filings.
And because the action was discontinued, the company remained on the register.
But viewed retrospectively, it forms another part of the corporate chronology.
By 2016, Lydac had already attracted compulsory strike-off action.
By 2018, it was in administration.
The Patent Was Granted During This Period
Now place that corporate history beside the intellectual-property history.
The European microvesicle patent associated with Stephen Ray's invention was granted in December 2015.
Lydac was identified as the original assignee.
That means something rather unusual was occurring during the same broad period.
On one side:
a company filing dormant accounts.
On the other:
a biotechnology company associated with potentially valuable intellectual property continuing through patent prosecution.
This does not necessarily conflict.
An intellectual-property holding company can legitimately be dormant or have very limited accounting activity.
But if that was Lydac's role, it makes the intellectual property potentially even more important.
Perhaps the patents were not merely one asset among many.
Perhaps they were among the company's principal assets.
That is something the insolvency documentation should establish.
Andrew Chancellor Was Not Merely an Officer — He Was Also Recorded as Having Significant Control
There is another detail worth examining.
Third-party company data reproducing Companies House information records Andrew Chancellor as a Person with Significant Control from 1 May 2016, with rights concerning the appointment and removal of directors. (Check Company)
This deserves verification against the underlying Companies House PSC filings before drawing more detailed conclusions about the precise legal basis of that control.
But if confirmed, it adds an important dimension.
Chancellor was not simply somebody whose name appeared briefly on the board.
The corporate record may indicate a deeper level of control.
And that makes understanding the decisions taken before administration more important.
The Statement of Affairs Is Critical
On 28 January 2019, Companies House records the filing of:
“Statement of affairs with form AM02SOA.”
The document runs to nine pages. (Companies House)
A statement of affairs in an administration can be one of the most revealing documents in an insolvency investigation.
It can identify assets.
It can identify creditors.
It can distinguish secured and unsecured claims.
It can provide estimated realisable values.
And it can expose the gap between what a company appeared to possess and what those assets were expected actually to produce for creditors.
For Lydac, one category is particularly important:
intellectual property.
Was the Intellectual Property Listed as an Asset?
This is the question I want answered before making any claim about where the technology went.
We already have independent patent evidence connecting Lydac with Stephen Ray's microvesicle intellectual property.
An official Canadian patent publication, for example, records Lydac Neuroscience Limited in connection with Canadian patent 2,711,218, with Stephen Ray identified as inventor. (Publications.gc.ca)
So when the company entered administration:
Were those patent rights still owned by Lydac?
If yes:
What value did the administrators place on them?
And if they were not listed:
Why not?
Perhaps they had already been assigned.
Perhaps they had been licensed.
Perhaps they had little remaining commercial value.
Perhaps particular territorial rights had lapsed.
Perhaps the company retained some rights but not others.
We should not guess.
But the absence or presence of intellectual property in the statement of affairs could materially change our understanding of the company.
The Administrator's Proposal Is Even More Important
Then, on 9 April 2019, a much larger document appeared.
Companies House describes it as:
“Statement of administrator's proposal.”
It runs to 31 pages. (Companies House)
This could potentially be the most important corporate document uncovered in the investigation so far.
Why?
Because an administrator's proposal ordinarily explains the administration and how the administrators intend to deal with the company.
Depending on the contents, it may reveal matters such as:
the company's background;
the circumstances leading to administration;
its financial position;
its creditors;
its assets;
attempts to realise those assets;
and the anticipated outcome for creditors.
The fact that this report exists means we do not need to speculate endlessly about why Lydac failed.
There is a contemporary professional record produced during the insolvency.
That is where the answer should be sought.
Creditors Formally Considered the Proposal
The process continued.
Companies House records the result of a meeting of creditors filed on 10 April 2019, immediately after the administrator's proposal. (Companies House)
That tells us Lydac's insolvency involved creditors with a formal financial interest in the outcome.
But we need the underlying documentation before making claims about who those creditors were or how much each was owed.
This distinction matters.
It would be irresponsible to take the existence of an insolvency and invent a story about investor losses.
The documents need to tell us.
Then Came the Administrator's Progress Report
On 19 July 2019, Companies House records another substantial filing:
Administrator's progress report — 17 pages. (Companies House)
This is another potentially critical document.
By this stage, the administrators had been controlling the company for approximately seven months.
If assets had been sold, recovered or realised during that period, a progress report may potentially record what happened.
For this investigation, I am particularly interested in whether it discusses:
patents;
intellectual property;
licences;
technology;
research assets;
or:
sales to third parties.
Because this is where the intellectual-property trail may finally move.
Administration Did Not Rescue Lydac
Whatever occurred during those months, Lydac did not emerge as a restored biotechnology company.
On 15 November 2019, the administration ended and the company moved into creditors' voluntary liquidation.
Companies House records an 18-page filing documenting the move. (Companies House)
The Gazette independently confirms the liquidation, recording Ian Robert and Christopher Purkiss as liquidators and stating that the appointment arose from a paragraph 83 exit from administration. (The Gazette)
This is important.
The administration had reached its conclusion.
The remaining company was going to be wound up.
Then the Liquidation Continued for More Than Five Years
Lydac's corporate story did not end in 2019.
Companies House records successive liquidators' statements of receipts and payments covering periods ending:
14 November 2020
14 November 2021
14 November 2022
and:
14 November 2023. (Companies House)
Then, on 9 January 2025, a 19-page return concerning the final meeting in the creditors' voluntary winding up was filed.
Finally, on:
9 April 2025
Lydac Neuroscience Limited was dissolved. (Companies House)
That means the insolvency process effectively stretched across more than six years from the appointment of administrators to dissolution.
For an investigative reconstruction, those years matter.
They potentially show what was recovered, what was paid out and what remained unresolved.
Follow the Money — But Follow the Assets Too
The phrase “follow the money” is useful.
But with a biotechnology company, it isn't enough.
We also have to follow the assets.
A conventional business might have:
property;
vehicles;
equipment;
stock;
cash;
and customer debts.
A biotechnology company can have something less visible but potentially much more valuable:
intellectual property.
Patents.
Know-how.
Manufacturing protocols.
Research data.
Licences.
Scientific documentation.
Trade secrets.
Those assets can survive even when the company that originally developed them does not.
That is why the Lydac insolvency matters to the wider Wellbeing investigation.
The Central Question Is No Longer Whether Lydac Failed
That is already established.
It entered administration.
Then liquidation.
Then dissolution.
The more important question is:
What survived Lydac?
Stephen Ray's scientific career certainly continued.
Andrew Chancellor's commercial career continued.
And the biological concepts surrounding extracellular material and cell-derived signalling products continued to appear in later regenerative-medicine activity.
But corporate continuity cannot simply be inferred from scientific continuity.
To establish a legal connection, we need the transaction.
Was There an Intellectual-Property Sale?
If administrators sold Lydac's patents, there may be records of the consideration received.
If they sold the business, the purchaser may be identifiable.
If intellectual property had already been transferred before administration, the administrator's report may discuss that fact.
If rights were licensed rather than sold, those licences may themselves have had value.
And if no meaningful value was attributed to the patents, that would raise a completely different set of questions.
Either way, the answer matters.
There Is Another Possibility
We also have to consider that the commercially important technology may have moved before the administrators arrived.
That possibility cannot be assumed.
But it must be tested.
If Lydac once held relevant intellectual property and did not hold it by December 2018, the next question becomes:
When did ownership change?
And then:
Who authorised the transfer?
Who received the asset?
What consideration was paid?
Was the transaction at arm's length?
Again, these are not allegations that an improper transfer occurred.
They are precisely the questions that arise when tracing valuable intellectual property through an insolvent company.
The Director's Role Requires Careful Treatment
Andrew Chancellor was Lydac's director when the company entered administration. (Companies House)
That is an established corporate fact.
It does not establish that he caused the insolvency.
It does not establish that he improperly transferred assets.
It does not establish that administrators criticised his conduct.
And it does not establish fraud or wrongdoing.
Unless the insolvency documents say otherwise, those conclusions should not be made.
But his position does mean that understanding Lydac's final years is directly relevant to understanding Chancellor's commercial history in biotechnology.
That is fair scrutiny.
Particularly when his later business activity involves technology associated with the same scientist whose earlier patent rights were connected with Lydac.
The Dormant Accounts Make the Financial Story Even More Important
There is one point I keep returning to.
Lydac's Companies House filings show dormant accounts immediately before administration. (Companies House)
Yet administration requires a financial problem serious enough to invoke a formal insolvency procedure.
That doesn't mean the two facts are incompatible.
But it means the administrator's explanation becomes essential.
What happened between the picture presented by those dormant accounts and the appointment of administrators in December 2018?
What liabilities existed?
When were they incurred?
Who funded the company?
Who was owed money?
What assets existed to meet those liabilities?
These are the financial questions Chapter Eight leaves firmly on the table.
What We Can Establish Today
The public record now allows several conclusions to be stated safely.
Lydac Neuroscience was a UK biotechnology research company incorporated in 2007 and ultimately dissolved in April 2025. (Companies House)
Andrew Chancellor became its director in November 2014. (Companies House)
The company filed dormant accounts for the financial years ending September 2015, 2016 and 2017. (Companies House)
It had also faced compulsory strike-off action in 2016, which was subsequently discontinued. (Companies House)
Administrators were appointed on 17 December 2018. (The Gazette)
A statement of affairs followed in January 2019.
A 31-page administrator's proposal followed in April.
A progress report followed in July.
And in November 2019, Lydac left administration and entered creditors' voluntary liquidation. (Companies House)
Liquidation continued until the company was eventually dissolved in 2025. (Companies House)
That sequence is documented.
What We Cannot Yet Establish
This is equally important.
I am not yet stating a figure for Lydac's debts.
I am not yet stating how much creditors lost.
I am not yet claiming investors lost a particular amount.
I am not yet claiming the patents were sold or transferred during the insolvency.
I am not claiming Chancellor acquired the intellectual property.
And I have found no basis at this stage to allege misconduct by Chancellor or Ray in connection with the insolvency.
Those conclusions require evidence inside the detailed insolvency documents.
The existence of administration is not enough.
But We Now Know Exactly Where to Look
And that is what makes Chapter Eight important.
The investigation has narrowed dramatically.
We no longer need to ask vaguely:
“What happened to Lydac?”
We can identify the exact documents that should contain the answers.
The January 2019 Statement of Affairs.
The April 2019 Administrator's Proposal.
The July 2019 Administrator's Progress Report.
The November 2019 administration-to-liquidation report.
And the subsequent liquidators' receipts-and-payments statements. (Companies House)
Those documents form the financial autopsy of Lydac Neuroscience.
Conclusion: The Company Died — But Did Its Most Valuable Asset Survive?
This investigation began by following Stephen Ray's science.
That led to patents.
The patents led to Lydac Neuroscience.
Lydac led to Andrew Chancellor.
And Chancellor's directorship led us straight into an insolvency file.
Now the question becomes considerably sharper.
Lydac entered administration in December 2018.
It failed to emerge as an independent operating biotechnology company.
It entered liquidation in November 2019.
And after years of winding up, it disappeared completely from the Companies House register in April 2025. (The Gazette)
But companies can disappear while their intellectual property survives.
That is why the next stage matters.
Because if Lydac's microvesicle intellectual property—or related scientific rights—left the company before or during insolvency, there should potentially be a destination.
A buyer.
An assignee.
A licensee.
A successor.
Or another legal owner.
And if we can identify that destination, we may finally be able to answer the question that has been building since Chapter Five:
Where did Stephen Ray's science go after Lydac Neuroscience failed?
Next: Chapter Nine — The Missing Asset: Who Got Lydac’s Intellectual Property?
We have identified the insolvency documents. Now the investigation becomes forensic: the administrator's reports, the statement of affairs, asset realisations and patent ownership records. Was Lydac's intellectual property sold, transferred or licensed—and who ultimately ended up controlling it?
Comments